PE20170299A1 - Proteinas agonistas de los receptores de trail de cadena simple - Google Patents

Proteinas agonistas de los receptores de trail de cadena simple

Info

Publication number
PE20170299A1
PE20170299A1 PE2016002016A PE2016002016A PE20170299A1 PE 20170299 A1 PE20170299 A1 PE 20170299A1 PE 2016002016 A PE2016002016 A PE 2016002016A PE 2016002016 A PE2016002016 A PE 2016002016A PE 20170299 A1 PE20170299 A1 PE 20170299A1
Authority
PE
Peru
Prior art keywords
agonists
proteins
single chain
trail receptors
chain trail
Prior art date
Application number
PE2016002016A
Other languages
English (en)
Inventor
Susan E Lappe
Darren C Phillips
Oliver Hill
Meinolf Thiemann
Christian Gieffers
Fritz G Buchanan
Original Assignee
Apogenix Ag
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag, Abbvie Inc filed Critical Apogenix Ag
Publication of PE20170299A1 publication Critical patent/PE20170299A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)

Abstract

Se refiere a una proteina agonista de los receptores de ligando inductor de apoptosis relacionado con el factor de necrosis tumoral (TRAIL) caracterizada porque comprende un polipeptido que tiene una secuencia de aminoacidos de SEQ ID N° 19 que comprende tres dominios de TRAIL solubles y un fragmento Fc. Tambien se refiere a una composicion. Dicha proteina no forma agregados de forma sustancial y son apropiadas para aplicaciones terapeuticas tal como el tratamiento de cancer
PE2016002016A 2014-04-23 2015-04-23 Proteinas agonistas de los receptores de trail de cadena simple PE20170299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
PE20170299A1 true PE20170299A1 (es) 2017-05-06

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002016A PE20170299A1 (es) 2014-04-23 2015-04-23 Proteinas agonistas de los receptores de trail de cadena simple

Country Status (37)

Country Link
US (4) US9908927B2 (es)
EP (2) EP3134430B1 (es)
JP (2) JP6523331B2 (es)
KR (2) KR20190135546A (es)
CN (2) CN111718424A (es)
AR (1) AR100168A1 (es)
AU (3) AU2015249649B2 (es)
BR (1) BR112016024515B1 (es)
CA (2) CA2946402C (es)
CL (1) CL2016002683A1 (es)
CR (1) CR20160516A (es)
CY (1) CY1120281T1 (es)
DK (1) DK3134430T3 (es)
DO (1) DOP2016000284A (es)
EC (1) ECSP16089579A (es)
ES (1) ES2672368T3 (es)
HR (1) HRP20180950T1 (es)
HU (1) HUE038914T2 (es)
IL (2) IL248244B (es)
LT (1) LT3134430T (es)
MA (2) MA45069A (es)
MX (2) MX2016013858A (es)
MY (1) MY181986A (es)
NO (1) NO2776305T3 (es)
PE (1) PE20170299A1 (es)
PH (1) PH12016502079B1 (es)
PL (1) PL3134430T3 (es)
PT (1) PT3134430T (es)
RS (1) RS57153B1 (es)
RU (1) RU2699285C2 (es)
SG (3) SG10201806465TA (es)
SI (1) SI3134430T1 (es)
TR (1) TR201806912T4 (es)
TW (2) TWI683825B (es)
UA (1) UA118286C2 (es)
UY (1) UY36095A (es)
WO (1) WO2015164588A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023646A2 (pt) * 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
WO2017068180A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
EP3423480A1 (en) * 2016-03-01 2019-01-09 The Board of Trustees of the University of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
JP2019518713A (ja) * 2016-03-16 2019-07-04 メリマック ファーマシューティカルズ インコーポレーティッド 癌療法のための改変ｔｒａｉｌ
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP2019517570A (ja) * 2016-06-13 2019-06-24 メリマック ファーマシューティカルズ インコーポレーティッド Ｔｒａｉｌベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US11578315B2 (en) 2017-08-11 2023-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
WO2019178433A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2019178438A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
CZ308214B6 (cs) 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
DE602006009786D1 (de) 2005-04-15 2009-11-26 Rappaport Family Inst For Res Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CA2860950C (en) 2007-07-10 2017-08-01 Apogenix Gmbh Tnf superfamily collectin fusion proteins
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
CN102317314A (zh) * 2008-10-10 2012-01-11 阿纳福公司 结合trail-r1和trail-r2的多肽
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
AU2010206681A1 (en) * 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
EP2516458A1 (en) 2009-12-22 2012-10-31 Novartis AG Tetravalent cd47-antibody constant region fusion protein for use in therapy
EP2560684A4 (en) 2010-04-13 2013-11-20 Medimmune Llc FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
US9717803B2 (en) * 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
AU2013291982B2 (en) 2012-07-18 2017-01-12 Apogenix Ag Shortened CD95-Fc variants

Also Published As

Publication number Publication date
EP3134430B1 (en) 2018-03-21
NO2776305T3 (es) 2018-01-27
WO2015164588A1 (en) 2015-10-29
MX2016013858A (es) 2017-08-02
US9908927B2 (en) 2018-03-06
CN106459221B (zh) 2020-09-01
PH12016502079A1 (en) 2016-12-19
PL3134430T3 (pl) 2018-08-31
US20240174731A1 (en) 2024-05-30
CA2946402C (en) 2023-02-28
IL248244B (en) 2020-03-31
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
JP2017513503A (ja) 2017-06-01
TW201620928A (zh) 2016-06-16
PH12016502079B1 (en) 2016-12-19
AU2015249649B2 (en) 2018-10-04
CL2016002683A1 (es) 2017-07-07
CA2946402A1 (en) 2015-10-29
DOP2016000284A (es) 2017-02-15
CR20160516A (es) 2017-05-10
HUE038914T2 (hu) 2018-12-28
UA118286C2 (uk) 2018-12-26
TW202024123A (zh) 2020-07-01
JP6523331B2 (ja) 2019-05-29
MX2019013587A (es) 2020-01-13
SG10201806465TA (en) 2018-08-30
PT3134430T (pt) 2018-04-20
HRP20180950T1 (hr) 2018-08-10
US20180222962A1 (en) 2018-08-09
JP2019162114A (ja) 2019-09-26
NZ725476A (en) 2023-09-29
CY1120281T1 (el) 2019-07-10
MY181986A (en) 2021-01-18
BR112016024515B1 (pt) 2020-03-31
EP3134430A1 (en) 2017-03-01
DK3134430T3 (en) 2018-05-22
AU2015249649A1 (en) 2016-11-10
US20210040178A1 (en) 2021-02-11
MA39770A (fr) 2015-10-29
BR112016024515A2 (pt) 2017-10-10
IL248244A0 (en) 2016-11-30
ECSP16089579A (es) 2018-05-31
KR20170012257A (ko) 2017-02-02
RU2699285C2 (ru) 2019-09-04
MA45069A (fr) 2019-04-03
SI3134430T1 (en) 2018-05-31
SG11201608767XA (en) 2016-11-29
US20150337027A1 (en) 2015-11-26
TWI747178B (zh) 2021-11-21
KR20190135546A (ko) 2019-12-06
AR100168A1 (es) 2016-09-14
EP3366699A1 (en) 2018-08-29
ES2672368T3 (es) 2018-06-14
RS57153B1 (sr) 2018-07-31
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
TWI683825B (zh) 2020-02-01
JP6714751B2 (ja) 2020-06-24
AU2020202247A1 (en) 2020-04-23
TR201806912T4 (tr) 2018-06-21
UY36095A (es) 2015-10-30
KR102079919B1 (ko) 2020-02-24
AU2018271369A1 (en) 2018-12-20
RU2016145608A (ru) 2018-05-28
LT3134430T (lt) 2018-05-10
IL272612A (en) 2020-03-31
SG10202111785VA (en) 2021-12-30
RU2016145608A3 (es) 2018-12-26

Similar Documents

Publication Publication Date Title
PE20170299A1 (es) Proteinas agonistas de los receptores de trail de cadena simple
ECSP18082207A (es) Neoantígenos y métodos de su uso
CO2017008047A2 (es) Polipéptidos que se unen a proteínas de la superfamilia del receptor del factor de necrosis tumoral
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
BR112018007296A2 (pt) conjugados de anticorpo compreendendo agonista de receptor tipo toll
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
MX2017006866A (es) Pares de unión para producción de péptidos.
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
PH12015502439A1 (en) Anti-cd38 antibodies and fusions to attenuated inferferon alpha-2b
EA201990017A1 (ru) Антитела к миостатину и способы их применения
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
EA201591661A1 (ru) Пептиды и композиции для лечения повреждений суставов
NZ725459A (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
PE20161152A1 (es) Anticuerpos y metodos de uso
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
CY1123738T1 (el) Προσδετες που ενισχυουν τη βιοδραστικοτητα των γοναδοτροπινων
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins